InnoCare Pharma Limited

SEHK:9969 Stock Report

Market Cap: HK$14.0b

InnoCare Pharma Past Earnings Performance

Past criteria checks 0/6

InnoCare Pharma has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 42.8% per year.

Key information

21.1%

Earnings growth rate

60.4%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate42.8%
Return on equity-7.0%
Net Margin-60.3%
Next Earnings Update11 Nov 2024

Recent past performance updates

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Jun 21
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Apr 02
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Feb 14
Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Oct 06
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

May 11
Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30
InnoCare Pharma (HKG:9969) Is Using Debt Safely

Revenue & Expenses Breakdown

How InnoCare Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:9969 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24781-471520817
31 Mar 24715-761560794
31 Dec 23739-631551757
30 Sep 23721-584598723
30 Jun 23757-867625732
31 Mar 23696-781606660
31 Dec 22625-887614649
30 Sep 22503-987562605
30 Jun 221,187-296516815
31 Mar 221,111-78475759
31 Dec 211,043-65437722
30 Sep 2198260337678
30 Jun 21102-266286356
31 Mar 2152-329222380
31 Dec 201-391158403
30 Sep 201-1,853131382
30 Jun 201-2,155105349
31 Mar 201-2,14886281
31 Dec 191-2,14167213
30 Sep 192-74251190
30 Jun 192-59229181
31 Mar 192-57124165
31 Dec 182-55018150
31 Dec 170-3421563

Quality Earnings: 9969 is currently unprofitable.

Growing Profit Margin: 9969 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 9969 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.1% per year.

Accelerating Growth: Unable to compare 9969's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9969 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Return on Equity

High ROE: 9969 has a negative Return on Equity (-6.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies